Table 1.
Baseline characteristics of patients (n = 14) included in the study.
| Age in years (median ± SD) | 57.2 ± 14.4 |
| Female | 9/14 |
| Disease duration in years (median ± SD) | 11.7 ± 8.1 |
| RF and/or ACPA seropositivity | 8/14 |
| Erosive disease | 12/14 |
| Baseline disease activity (DAS28CRP) (median ± SD) | 4.78 ± 1.11 |
| High | 5/14 |
| Moderate | 8/14 |
| Low | 1/14 |
| EULAR response at W16 | |
| Good | 6/14 |
| Moderate | 4/14 |
| None | 4/14 |
| Ongoing treatment | |
| cDMARD | 14/14 |
| Prednisone (<10 mg/d) | 3/14 |
| Previous bDMARD use | 0/14 |
| Biopsy localization | |
| Wrist | 8/14 |
| Metatarsophalangeal joint | 3/14 |
| Metacarpophalangeal joint | 1/14 |
| Knee | 2/14 |
ACPA, Anti Citrullinated Protein Antibody; bDMARD, Biological Disease-Modifying Anti-Rheumatic Drug; cDMARD, Classical Disease-Modifying Anti-Rheumatic Drug; SD, Standard Deviation; RF, Rheumatoid Factor.